Introduction
death, ACS
ISCHEMIC HEART DISEASE, ACUTE CORONARY SYNDROME
Patients with acute coronary syndrome (ACS) face the highest risk of death among patients with ischemic heart diseases.Rivaroxaban is a direct oral anticoagulant with both anti-Xa activity and antiplatelet effects.The safety and efficacy of short-term low-dose rivaroxaban in the acute phase of ACS remain unknown. To fill this evidence gap, we designed this feasibility equivalence and noninferiority trial to compare the safety and efficacy of low-dose rivaroxaban with enoxaparin in patients hospitalized with ACS, aiming to obtain primary data for the design of a definitive randomized clinical trial (RCT) with a sufficient sample size to answer this clinical question.